[Budget impact analysis of efavirenz daily dose reduction at the Verona University Hospital].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Transliterated Title:
      La riduzione del dosaggio giornaliero di efavirenz nella terapia antiretrovirale: impatto sul budget nell'Azienda Ospedaliera Universitaria Integrata di Verona.
    • Source:
      Publisher: Edizioni Internazionali srl Country of Publication: Italy NLM ID: 9613961 Publication Model: Print Cited Medium: Internet ISSN: 2532-8689 (Electronic) Linking ISSN: 11249390 NLM ISO Abbreviation: Infez Med Subsets: MEDLINE
    • Publication Information:
      Publication: Pavia, Italy : Edizioni Internazionali srl
      Original Publication: Roma : ElseĢ€v edizioni mediche
    • Subject Terms:
      Hospitals, University*; Benzoxazines/*economics ; Benzoxazines/*therapeutic use ; HIV Infections/*drug therapy ; HIV Infections/*economics ; Reverse Transcriptase Inhibitors/*economics ; Reverse Transcriptase Inhibitors/*therapeutic use; Adult ; Alkynes ; Budgets ; Cyclopropanes ; Dose-Response Relationship, Drug ; Female ; HIV-1/drug effects ; Humans ; Italy ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Viral Load/drug effects
    • Abstract:
      Efavirenz is a non-nucleoside-reverse-transcriptase-inhibitor used as part of highly-active-antiretroviral-therapy for the treatment of the human immunodeficiency virus (HIV) type 1 infection. The present paper aims to describing the impact of efavirenz dose reduction on the pharmaceutical budget at the Verona University Hospital. A budget impact analysis comparing two prescribing scenarios was conducted: all patients treated with the efavirenz full dose (600 mg per day) vs. a proportion of patients treated with a reduced dose (200-400 mg per day). All outpatients referring to the Infectious Disease Clinic in the period November 2009-October 2011 were selected. Out of 132 patients treated with efavirenz, 25 were not considered, mainly due to a too short treatment period. Of the remaining 107 patients, 68 received the full dose, while 39 received a reduced dosage. The analysis included the cost of the drug and of diagnostic tests, from the National Health Service perspective. The daily dose reduction of efavirenz saved 54,664 euros (a 30% expenditure reduction). In sum, new strategies for pharmaceutical system sustainability are necessary; despite forthcoming expiring patents of several drugs, spending on antiretroviral drugs is expected to rise. This paper suggests a way of linking clinical benefits and cost reduction.
    • Accession Number:
      0 (Alkynes)
      0 (Benzoxazines)
      0 (Cyclopropanes)
      0 (Reverse Transcriptase Inhibitors)
      JE6H2O27P8 (efavirenz)
    • Publication Date:
      Date Created: 20140624 Date Completed: 20151228 Latest Revision: 20201209
    • Publication Date:
      20240829
    • Accession Number:
      24955798